SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
QTRX

Quanterix Corp (NASDAQ:QTRX)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$1.96-$0.07 (-3.45%)
 
Market cap
$93.1M
Insider Score
Health Score
Analyst consensus
Listed since
Dec 7, 2017
Market Cap$93.06M-72.1%
Revenue (ttm)$148.15M+14.9%
Net Income-$111.18M-16.2%
EPS-$2.36-1.3%
Shares Out47.48M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,055,963
Open$1.96
Previous Close$2.03
Day's Range$1.79 - $2.03
52-Week Range$1.76 - $8.77
Beta1.04
AnalystsBuy
Price Target$3.00(+53.06%)
Earnings DateMar 2, 2027

About QTRX

Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.

Address
Building 1, Billerica, MA, 01821, US
Market Cap
93 million
Employees
450
Industrial Classification
Medical - Devices

Analyst consensus

Hold
0 Buy1 Hold0 SellAvg target $3.00 (+53.1%)

1 firm rating QTRX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From QTRX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-3.45%
5 Days
-32.41%
1 Month
-30.99%
6 Months
-27.14%
1 Year
-72.08%

$QTRX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in QTRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by QTRX's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

QTRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

QTRX Revenue by Segment or Geography

QTRX's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New QTRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to QTRX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in QTRX

VTIVanguard Morningstar Total Stock Market ETF$2.87M
IWMiShares Russell 2000 ETF$2.30M
VXFVanguard Extended Market ETF$1.45M
IWNiShares Russell 2000 Value ETF$795.29K
VTWOVanguard Russell 2000 ETF$729.72K
IBBiShares Biotechnology ETF$627.58K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from QTRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
56.92
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
58

News check: CEO departure is offset by business expansion (Alzheimer's testing access, partnerships) and Q3 earnings, showing mixed signals with underlying operational progress.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.64%
NIFEDirexion Fallen Knives ETF0.34%
FESCFirst Eagle Small Cap Equity ETF0.19%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.14%
IBBiShares Biotechnology ETF0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.